Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers

The blood–brain barrier (BBB) has a significant contribution to homeostasis and protection of the CNS. However, it also limits the crossing of therapeutics and thereby complicates the treatment of CNS disorders. To overcome this limitation, the use of nanocarriers for drug delivery across the BBB ha...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2020-01, Vol.15 (2), p.205-214
Main Authors: Mulvihill, John Je, Cunnane, Eoghan M, Ross, Aisling M, Duskey, Jason T, Tosi, Giovanni, Grabrucker, Andreas M
Format: Article
Language:English
Subjects:
BBB
brain
Brain cancer
Brain research
Cytotoxicity
drug targeting
exosomes
Experiments
Ligands
Lipids
liposomes nano
nanomedicines
nanoparticles
Peptides
PLGA
Proteins
Quantum dots
theranostics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The blood–brain barrier (BBB) has a significant contribution to homeostasis and protection of the CNS. However, it also limits the crossing of therapeutics and thereby complicates the treatment of CNS disorders. To overcome this limitation, the use of nanocarriers for drug delivery across the BBB has recently been exploited. Nanocarriers can utilize different physiological mechanisms for drug delivery across the BBB and can be modified to achieve the desired kinetics and efficacy. Consequentially, several nanocarriers have been reported to act as functional nanomedicines in preclinical studies using animal models for human diseases. Given the rapid development of novel nanocarriers, this review provides a comprehensive insight into the most recent advancements made in nanocarrier-based drug delivery to the CNS, such as the development of multifunctional nanomedicines and theranostics.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2019-0367